孕早期生化标记物结合超声筛查唐氏综合征  

First-trimester screening for trisomy 21 combining biochemistry and ultrasound in routine clinical practice

作　　者：李金春[1] 张长俊[1] 张燕妮[1] 徐悦凡[2] 周敏[2] 任晨春[2] 

机构地区：[1]天津市妇女儿童保健中心,天津市妇女保健所300050 [2]天津市中心妇产科医院

出　　处：《中国妇幼保健》2007年第3期385-387,共3页Maternal and Child Health Care of China

基　　金：天津市自然科学基金资助项目(项目编号:023612511)

摘　　要：目的：探讨孕早期唐氏综合征（DS）的产前筛查方法。方法：采用时间分辨免疫法对孕7-13周452例孕妇血清中PAPP—A和β-HCG两项血清标记物进行检测。同时用超声对其中孕10—13周的孕妇测量颈部透明带（nuchal translucency，NT）厚度。用Tl—risk风险统计软件进行风险率计算，以1：250作为高风险的切割值。结果：二联生化筛查7-13周的452例孕妇中，筛出高危孕妇45例，确诊DS胎儿1例；二联生化＋NT筛查10—13周的孕妇101例，筛出高危孕妇6例。结论：孕早期二联生化＋NT筛查DS胎儿，有望使产前诊断时间提前，且筛查结果的假阳性率降低。Objective： To assess the effectiveness of the combined test in the prenatal detection of trisomy 21 in the first - trimester. Methods： First - trimester maternal serum biochemical markers （ PAPP - A, β - HCG） were determined in maternal serum at 7 ～ 13 weeks. Fetal nuchal translucency were assessed at 10 ～ 13 weeks by ultrasound scan. A combined risk was estimated. When the risk was 1 ： 250 or above, it was regarded as the cut -off value of high risk. Results： Biochemistry screening： in 452 pregnant women, 45 cases were screened as high risk. One was identified as DS fetus. Biochemistry ＋ NT： in 101 pregnant women, 6 cases were screened as high risk. Conclusion： Screening for DS in the first trimester is feasible. The time of screening would be earlier than before a remarkably reduced false - positive observed.

关 键 词：唐氏综合征 生化标记物 孕早期筛查 颈部透明带 

分 类 号：R781.4[医药卫生—口腔医学]